Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 14/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499225 | 0.96 | CCR8 (0.91) | CCR8KCNH2SIGMAR1CCR3MCHR1 | |
| SCHEMBL6505246 | 0.96 | CCR8 (0.91) | CCR8KCNH2SIGMAR1CCR3 | |
| SCHEMBL6498549 | 0.92 | CCR8 (0.85) | CCR8KCNH2SIGMAR1ACKR3CCR3 | |
| SCHEMBL6495934 | 0.89 | CCR8 (0.80) | CCR8KCNH2SIGMAR1ACKR3CCR3 | |
| SCHEMBL6505985 | 0.87 | CCR8 (0.83) | CCR8KCNH2SIGMAR1CCR3 | |
| SCHEMBL6501162 | 0.86 | CCR8 (0.82) | CCR8KCNH2SIGMAR1CCR3 | |
| SCHEMBL6499354 | 0.82 | CCR8 (0.69) | CCR8KCNH2SIGMAR1 | |
| SCHEMBL6499853 | 0.81 | CCR8 (0.68) | CCR8KCNH2SIGMAR1 | |
| SCHEMBL6505970 | 0.80 | CCR8 (0.78) | CCR8KCNH2SIGMAR1 | |
| SCHEMBL7155259 | 0.80 | CCR8 (0.68) | CCR8KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) | 2019-09-03 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | CCR3, CCR5, CCR1 | CCR8 14/4885KCNH2 4859/4885SIGMAR1 2400/4885 |
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CCR8 1/4885KCNH2 4349/4885SIGMAR1 525/4885 |
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | CCR3, CCR5, CCR1 | CCR8 14/4885KCNH2 4861/4885SIGMAR1 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.